Clinical Trial Update: A Study to Evaluate the Botulinum Toxin Type A for Injection(HengLi®) in Subjects With Post-stroke Upper Limb Spasticity [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating HengLi (botulinum toxin type A) for injection in adults with post-stroke upper limb spasticity has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• HengLi® (Botulinum toxin type A)

Snippet

Sponsor: Lanzhou Institute of Biological Products Co., Ltd | Conditions: Cerebrovascular Accident | Phase 3 | Status: COMPLETED